Drug Profile
ABT 639
Alternative Names: ABT-639Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Analgesics
- Mechanism of Action T type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 12 Apr 2012 Phase-II clinical trials in Diabetic neuropathies in United Kingdom (unspecified route)
- 04 Nov 2011 Abbott completes a phase II trial in Diabetic neuropathies in the US, Mexico, France, Germany and the Czech Republic (NCT01345045)